"In the phase 3 randomized clinical trial, once-daily oral ivarmacitinib (4 or 8 mg) led to significant improvements in the ...

Explore Organon’s Q1 2025 earnings insights, featuring Nexplanon and Vtama growth, cost-saving measures, and a focus on deleveraging targets.

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that results from a Phase 1a ...

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory ...

Granuloma annulare causes a rash that’s easily mistaken for ringworm. This rash forms a clear circle with small, firm, ...

Dermatologists break down the most common circular rashes that aren’t ringworm, including hives, lupus, and atopic dermatitis ...

Providing a diverse range of perspectives from bullish to bearish, 9 analysts have published ratings on Incyte INCY in the ...

Skin Relief dry dog food by Rayne Nutrition was designed to help with the management of atopic dermatitis, osteoarthritis, ...

Starting in 2025, the Eylea franchise as a whole began to decline due to competitive pressure from long-acting Vabysmo, which competes with Eylea HD, and Pabvlu, a biosimilar version of the original ...

Alexis Smith uses her eczema to teach others about the condition, which has helped booster her confidence over time.

A phase 3 trial shows that ivarmacitinib improves symptoms in adults with moderate to severe atopic dermatitis compared with ...